Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

British Journal of Clinical Pharmacology

Volumn 44, Issue 2, 1997, Pages 190-194

  Eagling, V A ^a   Back, D J ^a   Barry, M G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

CYP450 isozymes; Inhibition; Protease inhibitors

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHLORZOXAZONE; CYTOCHROME P450 ISOENZYME; INDINAVIR; PHENACETIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TESTOSTERONE; TOLBUTAMIDE;

ADULT; ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEALKYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MALE; PRIORITY JOURNAL; SCHOOL CHILD; TESTOSTERONE METABOLISM;

EID: 0030852009     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00644.x     Document Type: Article

References (32)

1. McCune JM, Rabin LB, Feinberg, MB, et al. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 1988; 53: 55-67.
2. Debouck C, Metcalf BW. Human immunodeficiency virus protease: a target for AIDS therapy. Drug Dev Res 1990; 21: 1-17.
3. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996; 51: 701-712.
4. Collier AC, Coombs RW, Schoenfeld DA, et al. for the AIDS Clinical Trial Group. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996; 334: 1011-1017.
5. Danner SA, Carr A, Leonard JM, et al. for the European-Australian Collaborative Ritonavir Study Group. A short term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-1533.
6. Schapiro JM, Winters MA, Stewert F, et al. The effect of high dose saquinavir on viral load and CD4+ T cell counts in HIV-infected patients. Ann Intern Med 1996; 124: 1039-1050.
7. Notermans DW, de Wolf F, Foudraine NA, et al. The effects of an antiretroviral triple combination with ritonavir, AZT and 3TC. AIDS 1996; 10 (Suppl 2): S17.
8. Gulick R, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC). XI International Congress on AIDS. Vancouver, July 1996 (abstract No. Th.B 931).
9. Barry M, Gibbons S, Mulcahy F, Back D. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokin 1997; 32: 194-209.
10. Kumar GN, Rodrigues D, Buko AM, Denisson JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 423-431.
11. Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996; 24: 307-314.
12. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 277: 145-153.
13. Sahai J. Risks and synergies from drug interactions. AIDS 1996: 10 (Suppl 1): S21-S25.
14. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV infected patients. AIDS 1997; (in press).
15. Tassaneeyakul W, Birkett DJ, Veronese ME, et al. Specificity of substrate and inhibitor probes for human cytochromes P4501A1 and 1A2. J Pharmacol Exp Ther 1993; 265: 401-407.
16. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990; 252: 442-447.
17. Berthun F, Goasduff T, Lucas D, Dreano Y, Lebot MH, Menez JF. Interaction between 2 probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans. Pharmacogenetics 1995; 5: 72-79.
18. Waxman DJ, Lapenson DP, Aoyama T, Gelboin HV, Gonzalez FJ, Kozelkwa K. Steroid hormone hydroxylase specificities of eleven CDNA-expressed human cytochrome P450s. Arch Biochem Biophys 1991; 290: 160-166.
19. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein determination with the folin phenol reagent. J Biol Chem 1951; 193: 265-275.
20. Back DJ, Tjia JF, Karbwang J, Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol 1988; 26: 23-29.
21. Perelson AG, Neumann AU, Markowitz M, Leonard JM, Ho, DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 1582-1586.
22. Cameron DW, Hsu A, Granneman GR, et al. Pharmacokinetics of ritonavir-saquinavir combination therapy. AIDS 1996; 10 (Suppl 2): S16.
23. Hammer SM. Advances in antiretroviral therapy and viral load monitoring. AIDS 1996; 10 (Suppl 3): S1-S11.
24. Bourrie M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 1996; 277: 321-332.
25. Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 1966; 277: 105-112.
26. Maurice M, Pichard L, Daujat M, et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 1992; 6: 752-758.
27. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996; 276: 370-379.
28. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. N-demethylation of amitriptyline in vitro: Role of cytochrome P4503A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 1995; 275: 592-597.
29. Bertz R, Cao G, Cavanaugh JH, Hsu A, Granneman GR, Leonard JM. Effect of ritonavir on the pharmacokinetics of desipramine. XI International Congress on AIDS, Vancouver, July 1996 (abstract No. Mo.B.1201).
30. Heylen R, Miller R. Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients: Part 2. Genitourin Med 1997; 73: 5-11.
31. Hsu A, Granneman GR, Witt G, Cavanaugh JH, Leonard J. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline. XI International Congress on AIDS. Vancouver, July 1996 (abstract No. Mo.B. 1200).
32. Ouellet D, Hsu A, Qian J, Cavanaugh J, Leonard J, Granneman GR. Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy volunteers. XI International Congress on AIDS Vancouver, July 1996 (abstract No. Mo.B. 1198).